User profiles for "author:F Schettini"
Francesca SchettiniPhD - BME - Tobii Dynavox - Account Manager Italy Verified email at tobiidynavox.com Cited by 1085 |
[HTML][HTML] Early and late infections in newborns: where do we stand? A review
…, A Filaninno, E De Giorgi, F Schettini… - Pediatrics & …, 2016 - Elsevier
Neonatal sepsis still represents an important cause of mortality and morbidity among infants.
According to the onset, we can distinguish “early onset sepsis” when microbiological …
According to the onset, we can distinguish “early onset sepsis” when microbiological …
[HTML][HTML] CDK 4/6 inhibitors as single agent in advanced solid tumors
F Schettini, I De Santo, CG Rea, P De Placido… - Frontiers in …, 2018 - frontiersin.org
Cyclin-dependent kinases (CDK) 4/6 inhibitors, namely abemaciclib, palbociclib, and
ribociclib, interfere with cell cycle progression, induce cell senescence and might promote …
ribociclib, interfere with cell cycle progression, induce cell senescence and might promote …
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review …
M Giuliano, F Schettini, C Rognoni, M Milani… - The Lancet …, 2019 - thelancet.com
Background Although international guidelines support the administration of hormone
therapies with or without targeted therapies in postmenopausal women with hormone …
therapies with or without targeted therapies in postmenopausal women with hormone …
[HTML][HTML] Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
F Schettini, N Chic, F Brasó-Maristany, L Paré… - NPJ breast …, 2021 - nature.com
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification) …
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification) …
[HTML][HTML] Frequency and spectrum of PIK3CA somatic mutations in breast cancer
…, M Vidal, B González-Farré, E Sanfeliu, F Schettini… - Breast cancer …, 2020 - Springer
Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients
…, G Masera, A Piga, F Schettini… - British journal of …, 2002 - Wiley Online Library
In 1997, the Italian Ministry of Health created a special programme for the controlled
distribution of deferiprone to collect data and to evaluate its safety and effectiveness in long …
distribution of deferiprone to collect data and to evaluate its safety and effectiveness in long …
[HTML][HTML] Attention and P300-based BCI performance in people with amyotrophic lateral sclerosis
The purpose of this study was to investigate the support of attentional and memory
processes in controlling a P300-based brain-computer interface (BCI) in people with …
processes in controlling a P300-based brain-computer interface (BCI) in people with …
[HTML][HTML] Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
…, F Braso-Maristany, E Sanfeliu, L Pare, F Schettini… - …, 2022 - thelancet.com
Background Both clinical and genomic data independently predict survival and treatment
response in early-stage HER2-positive breast cancer. Here we present the development …
response in early-stage HER2-positive breast cancer. Here we present the development …
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis
Abstract Background HER2-positive (HER2+) breast cancer (BC) comprises all the four
PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be …
PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be …
Overall survival of CDK4/6-inhibitor–based treatments in clinically relevant subgroups of metastatic breast cancer: Systematic review and meta-analysis
F Schettini, F Giudici, M Giuliano… - JNCI: Journal of the …, 2020 - academic.oup.com
Background Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors+ endocrine therapy (ET)
prolonged progression-free survival as first-or second-line therapy for hormone receptor …
prolonged progression-free survival as first-or second-line therapy for hormone receptor …